Search

Innovations in GPP

This webinar on September 11 featured speakers from around the world with experience implementing GPP at research sites, within networks, and at the sponsorship level.

Breaking New Ground: Expanding Access to Lenacapavir—Lessons from Dolutegravir and the Future of HIV Prevention

Explore STIWatch.org and get the latest resources to navigate the IUSTI & STI Prevention meetings!

STIWatch.org is an updated platform designed to enhance understanding and advocacy for STI vaccine and diagnostics research, development, and rollout.

Lenacapavir

Second Pivotal Trial of Twice-Yearly HIV Prevention Injection Safe and Highly Effective

AVAC welcomes the groundbreaking results of the PURPOSE 2 HIV prevention study of twice-yearly injectable lenacapavir for PrEP among 3,200 cisgender men, transgender men, transgender women, and nonbinary individuals who have sex with partners assigned male at birth. Among more than 2,000 people in the trial who received lenacapavir, there were only two HIV infections.

Second Pivotal Trial of Twice-Yearly HIV Prevention Injection Safe and Highly Effective: PURPOSE 2 Trial Among Gay Men, Trans and Nonbinary People  

HIV self-testing and PrEP, fighting health misinformation, innovations in GPP, and more!

This week AVAC is hosting a webinar on Innovations in GPP, sharing two new briefs to support PrEP access, a new podcast on strategies to counter health misinformation, and much more!

Restrategizing Civil Society Engagement for Pandemic and Global Governance

Statement of Solidarity with the Nigerian Key Population Community on the Murder of their Leader, Christopher Ikpu Terfa: A Call for unity, solidarity, and government protection

Innovations in GPP, wins for U=U, expanding PrEP access and more!

A brand-new webinar highlighting the innovations of GPP, a roundup of recordings and materials from our August webinars and the latest PxPulse Advocacy Chronicles discussing a U=U win in South Africa in our roundup.